255 related articles for article (PubMed ID: 8127143)
1. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin toxicity in relation to the proliferative state of human hematopoietic cells.
Minderman H; Linssen PC; Wessels JM; Haanen C
Exp Hematol; 1991 Feb; 19(2):110-4. PubMed ID: 1991492
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
4. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
Van Der Lely N; De Witte T; Muus P; Raymakers R; Preijers F; Haanen C
Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
[TBL] [Abstract][Full Text] [Related]
6. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
Lemoli RM; Gulati SC; Strife A; Lambek C; Perez A; Clarkson BD
Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
8. The effects of transforming growth factor beta 3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood.
Strife A; Lambek C; Perez A; Darzynkiewicz Z; Skierski J; Gulati S; Haley JD; ten Dijke P; Iwata KK; Clarkson BD
Cancer Res; 1991 Sep; 51(18):4828-36. PubMed ID: 1893375
[TBL] [Abstract][Full Text] [Related]
9. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Grant S; Bhalla K; Arlin Z; Howe CW
Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
[TBL] [Abstract][Full Text] [Related]
10. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
Yalowich JC; Zucali JR; Gross M; Ross WE
Cancer Res; 1985 Oct; 45(10):4921-4. PubMed ID: 3861238
[TBL] [Abstract][Full Text] [Related]
11. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
12. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
McCrady CW; Li F; Pettit GR; Grant S
Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
[TBL] [Abstract][Full Text] [Related]
14. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
Curtis JE; Minden MD; Minkin S; McCulloch EA
Leukemia; 1995 Mar; 9(3):396-404. PubMed ID: 7533865
[TBL] [Abstract][Full Text] [Related]
15. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
16. Growth-inhibitory effect of 2-CdA on myeloid CFU-GM progenitors in normal human long-term bone marrow cultures and its compensation by G-CSF or IL-3.
Petzer AL; Geisen FH; Bilgeri R; Zilian U; Haun M; Herold M; Braunsteiner H; Konwalinka G
Exp Hematol; 1995 Jun; 23(6):529-34. PubMed ID: 7539380
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitro.
Dessypris EN; Brenner DE; Hande KR
Cancer Treat Rep; 1986 Apr; 70(4):487-90. PubMed ID: 3698042
[TBL] [Abstract][Full Text] [Related]
18. The role of methylcellulose on colony growth of human myeloid leukemic progenitors (AML-CFU).
Allieri MA; Douay L; Deloux J; Smadja N; Najman A; Gorin NC
Exp Hematol; 1990 Sep; 18(8):911-5. PubMed ID: 2387341
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
20. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.
Sarris AH; Talpaz M; Deisseroth AB; Estrov Z
Leukemia; 1996 May; 10(5):757-65. PubMed ID: 8656668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
